Research & Development

Eli Lilly Canada plays an integral role in the company’s global Research and Development division, Lilly Research Laboratories (LRL). Working as part of a global entity that transcends national borders, the R&D division of Lilly Canada is responsible for the discovery, development and clinical evaluation of Lilly’s new medicines and for providing ongoing scientific support for our existing marketed products.  In Canada, approximately 115 Lilly employees are employed in our R&D division.

Canadian Clinical Research

Eli Lilly & Company currently has an unprecedented number of molecules in clinical development, including potential new medicines for diseases such as diabetes, rheumatoid arthritis, Alzheimer's Disease and many types of cancer. Canadian experts are directly involved in much of this important research; in addition, Lilly Canada supports research on our marketed products to address important clinical and scientific questions. In 2008, Lilly Canada conducted more than 50 clinical trials in over 300 sites across the country, and invested more than $50 million in R&D in Canada.

Leading in Transparency with Lillytrials.com

Lilly understands that the health care community is looking for transparent answers that provide value to the health care decision-making process. Consistent with the company's policy of open disclosure, Lilly assumed a leading role in this area when, in 2004, Lilly became the first pharmaceutical company to voluntarily launch an online clinical trial registry, www.lillytrials.com.

Learn More About Lilly R&D

For a closer look at Lilly’s R&D strategy, the unique molecules in Lilly's clinical development pipeline, and Lilly’s Principles of Medical Research, please visit our global R&D website at www.lilly.com/research.